EPHA2 and prostate adenocarcinoma: In the previous reports, one family member, EphA2, is strongly overexpressed in many types of tumor, such as glioblastomas, ovarian cancers and prostate adenocarcinomas, and the increased expression of EphA2 correlates with enhanced metastatic potential and poor prognosis[9].